Clinical Trial Update: Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant [Phase 4]

View source ↗

Summary

Clinical trial on preemptive Zepatier treatment in HCV-positive donors to HCV-negative recipients in cardiac transplant was withdrawn (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Transplant Complication
• Hepatitis C

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: Raymond T. Chung, MD | Conditions: Cardiac Transplant Disorder, Hepatitis C | Phase 4 | Status: WITHDRAWN